MedTrace Logo

Irisin Levels in Patients With Charcot-Marie-Tooth (CMT) Disease

NCT04786522 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2021-03-10

No results posted yet for this study

Summary

Irisin is an exercise-mimetic myokine secreted by skeletal muscle. Compelling evidence in animal models and humans showed that Irisin prevents onset of musculoskeletal atrophy and its low serum levels are predictive of sarcopenia. The investigators evaluated the levels of irisin in patients affected by an hereditary motor and sensory neuropathy, namely Charcot-Marie-Tooth disease (CMT), in order to investigate possible key determinants of their muscle quality and possibly prevent the progressive distal weakness and muscle atrophy.

Conditions

  • Charcot-Marie-Tooth Disease

Interventions

DIAGNOSTIC_TEST

Bioimpedenziometry, Handgrip strenght evaluation

The measurement of body composition was performed using Bioimpedance (BIA 101, Akern srl, Pontassieve (FI), Italy). The handgrip dynamometer (Jamar, Sammons Preston, Bolingbrook, IL, USA) was used to determine the isometric force of the forearm.

DIAGNOSTIC_TEST

Evaluation on blood specimens

Serum samples were assayed for calcium, phosphorus, magnesium, iron, lactate dehydrogenase (Ldh), creatine phosphokinase (Cpk), creatine kinase myocardial band (Ckmmb), myoglobin, thyroid stimulating hormone (TSH), 25(OH)-Vitamin D, osteocalcin, bone alkaline phosphatase (b-ALP), C-terminal telopeptide of type I collagen (CTX-I), haptoglobin, sclerostin, myostatin, and Irisin. Irisin serum concentrations were detected using a competitive ELISA kit (AdipoGen, Liestal, Switzerland)

Sponsors & Collaborators

  • University of Bari

    lead OTHER

Principal Investigators

  • Michele Barone, prof. · University of Bari

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-02
Primary Completion
2020-10-31
Completion
2020-12-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04786522 on ClinicalTrials.gov